Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fesoterodine
Drug ID BADD_D00891
Description Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Indications and Usage For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
Marketing Status approved
ATC Code G04BD11
DrugBank ID DB06702
KEGG ID D07226
MeSH ID C526675
PubChem ID 6918558
TTD Drug ID D00BLL
NDC Product Code 47621-025; 50370-0047
UNII 621G617227
Synonyms fesoterodine | toviaz | fesoterodine fumarate
Chemical Information
Molecular Formula C26H37NO3
CAS Registry Number 286930-02-7
SMILES CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urge incontinence20.02.02.0080.001340%Not Available
Urinary hesitation20.02.02.0090.000496%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.003275%
Urinary retention20.02.02.0110.027039%
Urinary tract disorder20.08.01.0010.001092%Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urine flow decreased20.02.02.0120.000744%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.000496%
Ventricular extrasystoles02.03.04.0070.001092%Not Available
Vertigo17.02.12.002; 04.04.01.0030.002679%
Vision blurred17.17.01.010; 06.02.06.0070.008484%
Visual acuity reduced17.17.01.011; 06.02.10.0120.000496%
Visual impairment06.02.10.0130.001240%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.005458%Not Available
Musculoskeletal disorder15.03.05.025--Not Available
Hypoacusis04.02.01.0060.002431%
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Bladder spasm20.02.02.0130.000496%
General physical health deterioration08.01.03.0180.001240%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.001340%Not Available
Intervertebral disc protrusion15.10.01.0040.000496%Not Available
Gastrointestinal hypomotility07.02.02.0050.000496%Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Faecaloma07.01.03.0040.000992%Not Available
Pneumatosis intestinalis07.11.01.0430.000496%Not Available
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages